N. of patients (%) | N. of patients (%) | N. of patients (%) | |
---|---|---|---|
Tumour stage | pT1 | pT2 | pT3/4 |
Total 18 patients | 7 (38.9) | 7 (38.9) | 4 (22.2) |
Post-PST | ypT1 | ypT2 | ypT3/4 |
Total of 15 patients | 2 (13.3) | 8 (53.3) | 5 (33.3) |
Nodal stage | pNo | pN1 | pN2/3 |
Total of 22 patients | 8 (36.3) | 6 (27.2) | 8 (36.3) |
Post-PST | Nodal stage not determined | ypN2/3 | |
Total of 11 patients | 4 (36.3) | 7 (63.6) |
Monochemotherapy | N. of patients |
---|---|
Eribulin | 8 |
Taxane | 4 |
Vinorelbine | 3 |
Capecitabine | 3 |
Mitomycin | 1 |
Pegylated liposomal doxorubicin | 1 |
Carboplatin & gemcitabine | 3 |
Vinorelbine & capecitabine | 1 |
Trastuzumab | 6 |
Bevacizumab | 4 |
AI with everolimus & fulvestrant | 5 |
Areas of treated thorax wall | N. of patients (%) |
---|---|
On one side | 23 (69.7) |
On two sides | 7 (21.2) |
+ axilla | 5 |
+ upper arm | 3 |
+ dorsal | 5 |
+ supra/infraclavicular | 1 |
Metastasis localization | N. of patients (%) |
---|---|
Loco-regional - exclusively | 12 (36.3) |
Loco-regional + distal | 21 (63.6) |
1 organ affected | 15 (45.4) |
2 organs affected | 3 (9) |
> 2 organs affected | 3 (9) |
Metastases → pulmonary/pleural | 11 (33) |
Metastases → bone | 10 (30.3) |
Metastases → cerebral | 3 (9) |
Metastases → hepatic | 3 (9) |